Lactacystin augments the sulindac-induced apoptosis in HT-29 cells

被引：15
作者：
Choi, HJ
Kim, HH
Lee, HS
Huh, GY
Seo, SY
Jeong, JH
Kim, JM
Yoo, YH [1 ]
机构：
[1] Dong A Univ Coll Med, Dept Anat & Cell Biol, Pusan 602714, South Korea
[2] Dong A Univ Coll Med, Dept Gen Surg, Pusan 602714, South Korea
[3] Dong A Univ Coll Med, Dept Radiat Oncol, Pusan 602714, South Korea
[4] Dong A Univ Coll Med, Dept Pathol, Pusan 602714, South Korea
[5] Dong A Univ Coll Med, Dept Microbiol & Immunol, Pusan 602714, South Korea
来源：
APOPTOSIS | 2003年 / 8卷 / 03期
关键词：
apoptosis; colon cancer; lactacystin; proteasome; sulindac;
D O I：
10.1023/A:1023681007766
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The present study was conducted to explore the potential role of proteasome pathway in NSAIDs-induced apoptosis. We employed sulindac as a NSAID, and chose the lactacystin for inhibition of proteasome activity. Assessment of apoptosis and proteasome activity assay were undertaken. We demonstrated that sulindac treatment resulted in a decrease of proteasome activity, and that the co-treatment of a proteasome inhibitor lactacystin potentiated the extent of sulindac-induced apoptosis in HT-29 cells by augmentation of the decrease in proteasome activity. Elucidation of the mechanism underlying the regression of colon cancers by combinations of sulindac and lactacystin seems to be an immediate challenge for the near future.
引用
收藏
页码：301 / 305
页数：5
相关论文
共 20 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
    Chandra, J
    Niemer, I
    Gilbreath, J
    Kliche, KO
    Andreeff, M
    Freireich, EJ
    Keating, M
    McConkey, DJ
    [J]. BLOOD, 1998, 92 (11) : 4220 - 4229
  • [3] Chen F, 2000, CELL GROWTH DIFFER, V11, P239
  • [4] The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis
    Delic, J
    Masdehors, P
    Ömura, S
    Cosset, JM
    Dumont, J
    Binet, JL
    Magdelénat, H
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (07) : 1103 - 1107
  • [5] Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells
    Drexler, HCA
    Risau, W
    Konerding, MA
    [J]. FASEB JOURNAL, 2000, 14 (01) : 65 - 77
  • [6] Constitutive degradation of PML/RARα through the proteasome pathway mediates retinoic acid resistance
    Fanelli, M
    Minucci, S
    Gelmetti, V
    Nervi, C
    Gambacorti-Passerini, C
    Pelicci, PG
    [J]. BLOOD, 1999, 93 (05) : 1477 - 1481
  • [7] Golab J, 2000, ANTICANCER RES, V20, P1717
  • [8] Proteasomes play an essential role in thymocyte apoptosis
    Grimm, LM
    Goldberg, AL
    Poirier, GG
    Schwartz, LM
    Osborne, BA
    [J]. EMBO JOURNAL, 1996, 15 (15) : 3835 - 3844
  • [9] Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression
    Li, BY
    Dou, QP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) : 3850 - 3855
  • [10] Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
    Loda, M
    Cukor, B
    Tam, SW
    Lavin, P
    Fiorentino, M
    Draetta, GF
    Jessup, JM
    Pagano, M
    [J]. NATURE MEDICINE, 1997, 3 (02) : 231 - 234
12